David Chaplin
18Patents
4h-index
28Co-inventors
60Inventor score
Filing activity: Apr 13, 1987 → Aug 31, 2016
Most-cited inventions
| Patent | Title | Area | Cited by | Status |
|---|---|---|---|---|
| US4921963A | Platinum complexes with one radiosensitizing ligand | Human Necessities | 37 | Expired |
| US5026694A | Platinum complexes with one radiosensitizing ligand | Chemistry; Metallurgy | 27 | Expired |
| US6919324B2 | Functionalized stilbene derivatives as improved vascular targeting agents | Chemistry; Metallurgy | 9 | Expired |
| US7358236B1 | Control of acute hypertension and cardiotoxicity in patients treated with vascular targeting agents | Human Necessities | 4 | Expired |
| US6028111A | Compositions and use of benzamides and nicotinamides as anti-inflammatory agents | Chemistry; Metallurgy | 3 | Expired |
| US8198302B2 | Compositions and methods with enhanced therapeutic activity | Chemistry; Metallurgy | 2 | Active |
| US8877967B2 | Compositions and methods for inhibition of cathepsins | Chemistry; Metallurgy | 2 | Active |
| US9873668B2 | Compositions and methods for inhibition of cathepsins | Chemistry; Metallurgy | 2 | Active |
| US7001926B2 | Tubulin binding agents and corresponding prodrug constructs | Chemistry; Metallurgy | 1 | Expired |
| US9040500B2 | Method for treating hematopoietic neoplasms | Human Necessities | 1 | Active |
| US7384925B2 | Functionalized stilbene derivatives as improved vascular targeting agents | Chemistry; Metallurgy | 1 | Expired |
| US7091240B2 | Tubulin binding ligands and corresponding prodrug constructs | Chemistry; Metallurgy | 1 | Expired |
| US7456214B2 | Chromene-containing compounds with anti-tubulin and vascular targeting activity | Human Necessities | 1 | Expired |
| US9458103B2 | Compositions and methods for inhibition of cathepsins | Chemistry; Metallurgy | 1 | Active |
| USRE45720E1 | Functionalized stilbene derivatives as improved vascular targeting agents | General | 0 | Active |
| USRE45907E1 | Functionalized stilbene derivatives as improved vascular targeting agents | General | 0 | Active |
| US11419934B2 | Use of VDAS to enhance immunomodulating therapies against tumors | Chemistry; Metallurgy | 0 | Active |
| US6713517B1 | Use of aryl N-substituted carboxamides directly and as radio-and chemosensitizers for killing tumor and cancer cells and novel compounds for such use | Chemistry; Metallurgy | 0 | Expired |
Source: USPTO / EPO open patent data. Inventor disambiguation is heuristic; counts are objective bibliographic measures.